WO1998006415A3 - Anti-chlamydial methods and materials - Google Patents

Anti-chlamydial methods and materials Download PDF

Info

Publication number
WO1998006415A3
WO1998006415A3 PCT/US1997/013810 US9713810W WO9806415A3 WO 1998006415 A3 WO1998006415 A3 WO 1998006415A3 US 9713810 W US9713810 W US 9713810W WO 9806415 A3 WO9806415 A3 WO 9806415A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
chlamydial
materials
chlamydial infection
bpi
Prior art date
Application number
PCT/US1997/013810
Other languages
French (fr)
Other versions
WO1998006415A2 (en
Inventor
Lewis H Lambert Jr
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Priority to CA002263181A priority Critical patent/CA2263181C/en
Priority to EP97936420A priority patent/EP0918533B1/en
Priority to AT97936420T priority patent/ATE226442T1/en
Priority to JP10509836A priority patent/JP2001500117A/en
Priority to NZ334041A priority patent/NZ334041A/en
Priority to AU39094/97A priority patent/AU741480B2/en
Priority to DE69716605T priority patent/DE69716605T2/en
Publication of WO1998006415A2 publication Critical patent/WO1998006415A2/en
Publication of WO1998006415A3 publication Critical patent/WO1998006415A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal/permeability-inducing (BPI) protein product.
PCT/US1997/013810 1996-08-09 1997-08-07 Anti-chlamydial methods and materials WO1998006415A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002263181A CA2263181C (en) 1996-08-09 1997-08-07 Anti-chlamydial methods and materials
EP97936420A EP0918533B1 (en) 1996-08-09 1997-08-07 Anti-chlamydial methods and materials
AT97936420T ATE226442T1 (en) 1996-08-09 1997-08-07 ANTI-CHLAMYDIA METHODS AND MEANS
JP10509836A JP2001500117A (en) 1996-08-09 1997-08-07 Anti-Chlamydia methods and substances
NZ334041A NZ334041A (en) 1996-08-09 1997-08-07 Anti-chlamydial activity of BPI (bactericidal/permeability increasing proteins) protein products against chlamydia infected host cells
AU39094/97A AU741480B2 (en) 1996-08-09 1997-08-07 Anti-chlamydial methods and materials
DE69716605T DE69716605T2 (en) 1996-08-09 1997-08-07 ANTI-CHLAMYDIA METHOD AND MEANS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/694,843 US5888973A (en) 1996-08-09 1996-08-09 Anti-chlamydial uses of BPI protein products
US08/694,843 1996-08-09

Publications (2)

Publication Number Publication Date
WO1998006415A2 WO1998006415A2 (en) 1998-02-19
WO1998006415A3 true WO1998006415A3 (en) 1998-05-14

Family

ID=24790487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013810 WO1998006415A2 (en) 1996-08-09 1997-08-07 Anti-chlamydial methods and materials

Country Status (10)

Country Link
US (3) US5888973A (en)
EP (1) EP0918533B1 (en)
JP (1) JP2001500117A (en)
CN (1) CN1232401A (en)
AT (1) ATE226442T1 (en)
AU (1) AU741480B2 (en)
CA (1) CA2263181C (en)
DE (1) DE69716605T2 (en)
NZ (1) NZ334041A (en)
WO (1) WO1998006415A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
WO1998006435A2 (en) * 1996-08-14 1998-02-19 Vanderbilt University COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY $i(CHLAMYDIA)
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6884784B1 (en) * 1997-05-06 2005-04-26 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6153584A (en) 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
US7041644B2 (en) 1999-04-01 2006-05-09 Xoma Technology Therapeutic uses of BPI protein products in BPI-deficient humans
WO2002055099A2 (en) * 2000-12-01 2002-07-18 Xoma Technology Ltd Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
US20040029254A1 (en) * 2002-05-15 2004-02-12 University Of Washington Method of screening anti-bacterial agents for effectiveness in treating persistant intracellular infections
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
WO2006113526A2 (en) * 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
US10602795B2 (en) 2017-01-26 2020-03-31 Bell Sports, Inc. Helmet comprising a segmented shell

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001486A1 (en) * 1987-08-11 1989-02-23 New York University Biologically active bactericidal/permeability-increasing protein fragments
WO1995024209A1 (en) * 1994-03-11 1995-09-14 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
WO1996001647A1 (en) * 1994-07-11 1996-01-25 Xoma Corporation Anti-protozoan methods and materials
WO1996021436A1 (en) * 1995-01-13 1996-07-18 Xoma Corporation Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
EP0563222B1 (en) * 1990-12-03 1998-02-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
JPH07502642A (en) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド A novel form of liposaccharide binding protein (LBP)
EP0642579B1 (en) * 1992-05-19 1999-04-07 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
DE69428521T2 (en) * 1993-02-02 2002-05-23 Xoma Technology Ltd MEDICINAL COMPOSITIONS CONTAINING A BACTERICIDAL PERMEABILITY-INCREASING PROTEIN AND A SURFACTANT
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
WO1994020129A1 (en) * 1993-03-12 1994-09-15 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
ATE169304T1 (en) * 1993-03-12 1998-08-15 Xoma Corp BIOLOGICALLY ACTIVE PEPTIDES FROM FUNCTIONAL DOMAIN OF THE BACTERICIDE/PERMEABILITY-INCREASE PROTEINS AND THEIR USE
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
ATE202482T1 (en) * 1993-03-12 2001-07-15 Xoma Technology Ltd THERAPEUTIC USES OF ANTIBACTERIAL/PERMEABILITY-INCREASE PROTEIN PRODUCTS
AU6522794A (en) * 1993-03-22 1994-10-11 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
JPH08511682A (en) * 1993-04-30 1996-12-10 インサイト ファーマシューティカルズ，インク． Recombinant BPI protein and LBP protein, nucleic acid molecule encoding the same, production method thereof and use thereof
AU7175694A (en) * 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
DE69431922T2 (en) * 1993-07-02 2003-11-13 Incyte Pharma Inc GLYCOSILIZED AND NONGLYCOLIZED BACTERICIDES / PERMEABILITY INCREASING PROTEINS AND METHODS FOR THEIR PRODUCTION
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
CN1133634A (en) * 1993-09-22 1996-10-16 爱克斯欧玛公司 Method for quantifying BPI in body fluids
US5466580A (en) * 1993-09-22 1995-11-14 Xoma Corporation Method for quantifying BPI in body fluids
JPH09502987A (en) * 1993-09-22 1997-03-25 ゾーマ コーポレイション Method of treating Gram-negative bacterial infections by administration of bactericidal / permeabilized (BPI) protein products and antibiotics
EP0722333B1 (en) * 1993-10-05 2004-06-16 XOMA Technology Ltd. Bpi-protein-products for depressed reticuloendothelial system function
MX9602570A (en) * 1994-01-14 1997-04-30 Xoma Corp Anti-fungal methods and materials.
PT754050E (en) * 1994-01-14 2002-11-29 Xoma Technology Ltd METHODS AND MATERIALS AGAINST GRAM-POSITIVE BACTERIA
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
AU709738B2 (en) * 1994-09-15 1999-09-02 Xoma Corporation Anti-fungal peptides
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
AU727085B2 (en) * 1995-07-20 2000-11-30 Xoma Corporation Anti-fungal peptides
EP0861088A1 (en) * 1995-11-14 1998-09-02 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
WO1997042966A1 (en) * 1996-05-10 1997-11-20 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia
US5746753A (en) * 1996-05-13 1998-05-05 Boston Scientific Corporation Needle grasping apparatus
DE69719754D1 (en) * 1996-05-23 2003-04-17 Xoma Technology Ltd THERAPEUTIC USE OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BREEDING THROUGH TRAUMA
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001486A1 (en) * 1987-08-11 1989-02-23 New York University Biologically active bactericidal/permeability-increasing protein fragments
WO1995024209A1 (en) * 1994-03-11 1995-09-14 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
WO1996001647A1 (en) * 1994-07-11 1996-01-25 Xoma Corporation Anti-protozoan methods and materials
WO1996021436A1 (en) * 1995-01-13 1996-07-18 Xoma Corporation Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
L. LAMBERT ET AL.: "SUSCEPTIBILITY OF CHLAMYDIA TRACHOMATIS TO RECOMBINANT BACTERICIDAL/PERMEABILITY INCREASING PROTEIN (RBPI21).", ABSTRACTS OF THE 36TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 15 September 1996 (1996-09-15) - 18 September 1996 (1996-09-18), pages 141, XP002058449 *
R.D. INMAN ET AL.: "COMPARATIVE MICROBICIDAL ACTIVITY OF SYNOVIAL FLUID ON ARTHRITOGENIC ORGANISMS.", CLIN. EXP. IMMUNOL., vol. 104, no. 1, April 1996 (1996-04-01), pages 80 - 85, XP002058450 *

Also Published As

Publication number Publication date
DE69716605T2 (en) 2003-06-26
EP0918533B1 (en) 2002-10-23
WO1998006415A2 (en) 1998-02-19
AU741480B2 (en) 2001-11-29
US6583116B1 (en) 2003-06-24
JP2001500117A (en) 2001-01-09
NZ334041A (en) 2000-10-27
US6162788A (en) 2000-12-19
CA2263181C (en) 2003-03-18
ATE226442T1 (en) 2002-11-15
DE69716605D1 (en) 2002-11-28
AU3909497A (en) 1998-03-06
CA2263181A1 (en) 1998-02-19
CN1232401A (en) 1999-10-20
EP0918533A2 (en) 1999-06-02
US5888973A (en) 1999-03-30

Similar Documents

Publication Publication Date Title
WO1998006415A3 (en) Anti-chlamydial methods and materials
AU4770596A (en) Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products
AU1679795A (en) Anti-fungal methods and materials
AU3985397A (en) Fragrance delivery systems for personal care articles
CY2424B1 (en) Pharmaceutical composition for use in treatment ofdiabetes.
WO2000072876A3 (en) Prevention and treatment of amyloidogenic disease
HUP9904174A3 (en) Pharmaceutical composition for transdermic delivery
ZA966075B (en) Protein formulation.
IL110024A0 (en) Protein drugs delivery system
AU2967595A (en) Anti-protozoan methods and materials
AU8800598A (en) B7-binding molecules for treating immune diseases
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
AU6522396A (en) Composition for cleaning or treating human or animal hair
AU4188296A (en) Processed whey protein
ZA976967B (en) Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the of said device.
CA2173611A1 (en) Method of treating depressed reticuloendothelial system function
EP0744176A3 (en) Methods for inhibiting bone loss
EP0886649A4 (en) Protein occlusion for delivery of small molecules
EP0821694A4 (en) Conotoxin peptides
EP1304118A3 (en) Therapeutic uses and formulations for BPI protein products.
ZA964198B (en) Treatment regime for skin.
AU7368898A (en) Human translocation associated protein
ZA968185B (en) Protein.
ZA9610761B (en) Medical treatment.
HUP9903978A3 (en) Use of inhibitors of protein glycation for the treatment of type ii diabetes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97198452.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 334041

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1997936420

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2263181

Country of ref document: CA

Ref document number: 2263181

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1998 509836

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/001366

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1997936420

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1997936420

Country of ref document: EP